What is it about?
BRAF mutated thyroid cancer has worse prognosis. Dabrafenib/Trametinib is an important treatment option for BRAF mutated anaplastic thyroid cancer. However, dabrafenib/trametinib has distinct adverse events such as feverscene. Encorafenib/Trametinib is another option of BRAF/MEK inhibition. We investigated efficacy and safety of encorfenib/binimetinib for previously treated BRAF mutated thyroid cancer patients in a prospective phase II trial.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Encorafenib/binimetinib shows promising efficacy and manageable safety profiles for patients with BRAF mutated thyroid cancer including papillary thyroid cancer and anaplastic thyroid cancer. This combination is a new treatment option for this population.
Perspectives
Encorafenib/binimetinib should be another treatment option for BRAF mutated thyroid cancer patients with different safety profile from dabrafenib/trametinib.
Naomi Kiyota
Kobe University Hospital
Read the Original
This page is a summary of: A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan, Thyroid, March 2024, Mary Ann Liebert Inc,
DOI: 10.1089/thy.2023.0547.
You can read the full text:
Contributors
The following have contributed to this page
